1887

Journal of General Virology header logo

Volume 98, Issue 9

The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development Free

Abstract

Between the 1980s and 1990s, three assays were developed for diagnosis of human cytomegalovirus (HCMV) infections: leuko (L)-antigenemia, -viremia and -DNAemia, detecting viral protein pp65, infectious virus and viral DNA, respectively, in circulating leukocytes Repeated initial attempts to reproduce the three assays using laboratory-adapted strains and infected cell cultures were consistently unsuccessful. Results were totally reversed when wild-type HCMV strains were used to infect either fibroblasts or endothelial cells. Careful analysis and sequencing of plaque-purified viruses from recent clinical isolates drew attention to the ULb′ region of the HCMV genome. Using bacterial artificial chromosome technology, it was shown by both gain-of-function and loss-of-function experiments that UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. In addition, a number of clinical isolates passaged in human fibroblasts had lost both properties (leuko-tropism and endothelial cell-tropism) when displaying a mutation in the UL131-128 locus (referred to as UL128L). In the following years, it was shown that pUL128L was complexed with gH and gL to form the pentameric complex (PC), which is required to infect endothelial, epithelial and myeloid cells. The immune response to PC was studied extensively, particularly its humoral component, showing that the great majority of the neutralizing antibody response is directed to PC. Although anti-HCMV antibodies may act with other mechanisms than mere neutralizing activity, these findings definitely favour their protective activity, thus paving the way to the development of a potentially protective HCMV vaccine.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): human cytomegalovirus , pentamer complex and vaccine
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000882
2017-09-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/9/2215.html?itemId=/content/journal/jgv/10.1099/jgv.0.000882&mimeType=html&fmt=ahah

References

  1. Pass RF. Cytomegalovirus infection. Pediatr Rev 2002; 23:163–170 [View Article][PubMed]
     [Google Scholar]
  2. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 2013; 45:260–271 [View Article][PubMed]
     [Google Scholar]
  3. Boechk M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematol Am Soc Hematol Educ Program 2011; 2011:305–309
     [Google Scholar]
  4. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233–239 [View Article][PubMed]
     [Google Scholar]
  5. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008–1011 [View Article][PubMed]
     [Google Scholar]
  6. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004; 78:10023–10033 [View Article][PubMed]
     [Google Scholar]
  7. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005; 79:10330–10338 [View Article][PubMed]
     [Google Scholar]
  8. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C et al. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 2006; 87:2451–2460 [View Article][PubMed]
     [Google Scholar]
  9. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005; 102:18153–18158 [View Article][PubMed]
     [Google Scholar]
  10. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008; 82:60–70 [View Article][PubMed]
     [Google Scholar]
  11. van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM et al. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988; 26:2531–2535[PubMed]
     [Google Scholar]
  12. Grazia Revello M, Zavattoni M, Percivalle E, Grossi P, Gerna G. Correlation between immunofluorescent detection of human cytomegalovirus immediate early antigens in polymorphonuclear leukocytes and viremia. J Infect Dis 1989; 160:159–160 [View Article][PubMed]
     [Google Scholar]
  13. Revello MG, Percivalle E, di Matteo A, Morini F, Gerna G. Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol 1992; 73:437–442 [View Article][PubMed]
     [Google Scholar]
  14. Geballe AP, Leach FS, Mocarski ES. Regulation of cytomegalovirus late gene expression: gamma genes are controlled by posttranscriptional events. J Virol 1986; 57:864–874[PubMed]
     [Google Scholar]
  15. Gerna G, Zipeto D, Parea M, Revello MG, Silini E et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991; 164:488–498 [View Article][PubMed]
     [Google Scholar]
  16. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30:1232–1237[PubMed]
     [Google Scholar]
  17. Gerna G, Revello MG, Percivalle E, Zavattoni M, Parea M et al. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 1990; 28:2681–2688[PubMed]
     [Google Scholar]
  18. Zipeto D, Revello MG, Silini E, Parea M, Percivalle E et al. Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients. J Clin Microbiol 1992; 30:527–530[PubMed]
     [Google Scholar]
  19. Fox JC, Griffiths PD, Emery VC. Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 1992; 73:2405–2408 [View Article][PubMed]
     [Google Scholar]
  20. Gerna G, Zipeto D, Percivalle E, Parea M, Revello MG et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 1992; 166:1236–1244 [View Article][PubMed]
     [Google Scholar]
  21. Gerna G, D'Arminio Monforte A, Zavattoni M, Sarasini A, Testa L et al. Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy. AIDS 1998; 12:118–120[PubMed]
     [Google Scholar]
  22. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998; 177:1170–1175 [View Article][PubMed]
     [Google Scholar]
  23. Lang DJ, Ebert PA, Rodgers BM, Boggess HP, Rixse RS. Reduction of postperfusion cytomegalovirus-infections following the use of leukocyte depleted blood. Transfusion 1977; 17:391–395 [View Article][PubMed]
     [Google Scholar]
  24. Winston DJ, Ho WG, Howell CL, Miller MJ, Mickey R et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 1980; 93:671–675 [View Article][PubMed]
     [Google Scholar]
  25. Arora N, Novak Z, Fowler KB, Boppana SB, Ross SA. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 2010; 202:1800–1803 [View Article][PubMed]
     [Google Scholar]
  26. Revello MG, Furione M, Rognoni V, Arossa A, Gerna G. Cytomegalovirus DNAemia in pregnant women. J Clin Virol 2014; 61:590–592 [View Article][PubMed]
     [Google Scholar]
  27. Gerna G, Furione M, Baldanti F, Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994; 32:2709–2717[PubMed]
     [Google Scholar]
  28. Plachter B, Sinzger C, Jahn G. Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 1990; 46:195–261 [CrossRef]
     [Google Scholar]
  29. Hinnant KL, Rotterdam HZ, Bell ET, Tapper ML. Cytomegalovirus infection of the alimentary tract: a clinicopathological correlation. Am J Gastroenterol 1986; 81:944–950[PubMed]
     [Google Scholar]
  30. Melnick JL, Petrie BL, Dreesman GR, Burek J, Mccollum CH et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2:644–647 [View Article][PubMed]
     [Google Scholar]
  31. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol 1991; 138:563–567[PubMed]
     [Google Scholar]
  32. Myerson D, Hackman RC, Nelson JA, Ward DC, Mcdougall JK. Widespread presence of histologically occult cytomegalovirus. Hum Pathol 1984; 15:430–439 [View Article][PubMed]
     [Google Scholar]
  33. Gerna G, Baldanti F, Revello MG. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol 2004; 65:381–386 [View Article][PubMed]
     [Google Scholar]
  34. Percivalle E, Revello MG, Vago L, Morini F, Gerna G. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J Clin Invest 1993; 92:663–670 [View Article][PubMed]
     [Google Scholar]
  35. Gerna G, Percivalle E, Baldanti F, Sozzani S, Lanzarini P et al. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 2000; 74:5629–5638 [View Article][PubMed]
     [Google Scholar]
  36. Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S et al. In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 1998; 101:2686–2692 [View Article][PubMed]
     [Google Scholar]
  37. Revello MG, Baldanti F, Percivalle E, Sarasini A, de-Giuli L et al. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 2001; 82:1429–1438 [View Article][PubMed]
     [Google Scholar]
  38. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36:3585–3589[PubMed]
     [Google Scholar]
  39. Sedmak DD, Knight DA, Vook NC, Waldman JW. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation 1994; 58:1379–1385[PubMed]
     [Google Scholar]
  40. Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 1993; 78:405–412[PubMed]
     [Google Scholar]
  41. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301–314 [View Article][PubMed]
     [Google Scholar]
  42. Waldman WJ, Knight DA, Huang EH, Sedmak DD. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model. J Infect Dis 1995; 171:263–272 [View Article][PubMed]
     [Google Scholar]
  43. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974; 1:1–5 [View Article][PubMed]
     [Google Scholar]
  44. Plotkin SA, Farquhar J, Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976; 134:470–475 [View Article][PubMed]
     [Google Scholar]
  45. Waldman WJ, Roberts WH, Davis DH, Williams MV, Sedmak DD et al. Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells. Arch Virol 1991; 117:143–164 [View Article][PubMed]
     [Google Scholar]
  46. Radsak K, Fuhrmann R, Franke RP, Schneider D, Kollert A et al. Induction by sodium butyrate of cytomegalovirus replication in human endothelial cells. Arch Virol 1989; 107:151–158 [View Article][PubMed]
     [Google Scholar]
  47. Gerna G, Percivalle E, Baldanti F, Revello MG. Lack of transmission to polymorphonuclear leukocytes and human umbilical vein endothelial cells as a marker of attenuation of human cytomegalovirus. J Med Virol 2002; 66:335–339 [View Article][PubMed]
     [Google Scholar]
  48. Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ et al. Sequential mutations associated with adaptation of Human cytomegalovirus to growth in cell culture. J Gen Virol 2010; 91:1535–1546 [View Article][PubMed]
     [Google Scholar]
  49. Gerna G, Percivalle E, Sarasini A, Baldanti F, Revello MG. The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J Gen Virol 2002; 83:1993–2000 [View Article][PubMed]
     [Google Scholar]
  50. Gerna G, Percivalle E, Sarasini A, Baldanti F, Campanini G et al. Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 2003; 84:1431–1436 [View Article][PubMed]
     [Google Scholar]
  51. Baldanti F, Revello MG, Percivalle E, Labò N, Gerna G. Genomes of the endothelial cell-tropic variant and the parental Toledo strain of human cytomegalovirus are highly divergent. J Med Virol 2003; 69:76–81 [View Article][PubMed]
     [Google Scholar]
  52. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES et al. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996; 70:78–83[PubMed]
     [Google Scholar]
  53. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 2001; 11:191–200 [View Article][PubMed]
     [Google Scholar]
  54. Sinzger C, Schmidt K, Knapp J, Kahl M, Beck R et al. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol 1999; 80:2867–2877 [View Article][PubMed]
     [Google Scholar]
  55. Maccormac LP, Grundy JE. Two clinical isolates and the Toledo strain of cytomegalovirus contain endothelial cell tropic variants that are not present in the AD169, Towne, or Davis strains. J Med Virol 1999; 57:298–307 [View Article][PubMed]
     [Google Scholar]
  56. Kahl M, Siegel-Axel D, Stenglein S, Jahn G, Sinzger C. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol 2000; 74:7628–7635 [View Article][PubMed]
     [Google Scholar]
  57. Kabanova A, Marcandalli J, Zhou T, Bianchi S, Baxa U et al. Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat Microbiol 2016; 1:16082 [View Article][PubMed]
     [Google Scholar]
  58. Wu Y, Prager A, Boos S, Resch M, Brizic I et al. Human cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-α as a key for entry. PLoS Pathog 2017; 13:e1006281 [View Article][PubMed]
     [Google Scholar]
  59. Stegmann C, Hochdorfer D, Lieber D, Subramanian N, Stöhr D et al. A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells. PLoS Pathog 2017; 13:e1006273 [View Article][PubMed]
     [Google Scholar]
  60. Ciferri C, Chandramouli S, Donnarumma D, Nikitin PA, Cianfrocco MA et al. Structural and biochemical studies of HCMV gH/gL/gO and pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci USA 2015; 112:1767–1772 [View Article][PubMed]
     [Google Scholar]
  61. Zhou M, Yu Q, Wechsler A, Ryckman BJ. Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J Virol 2013; 87:9680–9690 [View Article][PubMed]
     [Google Scholar]
  62. Li G, Nguyen CC, Ryckman BJ, Britt WJ, Kamil JP. A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism. Proc Natl Acad Sci USA 2015; 112:4471–4476 [View Article][PubMed]
     [Google Scholar]
  63. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC. A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 2010; 84:2585–2596 [View Article][PubMed]
     [Google Scholar]
  64. Zhou M, Lanchy JM, Ryckman BJ. Human cytomegalovirus gH/gL/gO promotes the fusion step of entry into all cell types, whereas gH/gL/UL128-131 broadens virus tropism through a distinct mechanism. J Virol 2015; 89:8999–9009 [View Article][PubMed]
     [Google Scholar]
  65. Vanarsdall AL, Howard PW, Wisner TW, Johnson DC. Human cytomegalovirus gH/gL forms a stable complex with the fusion protein gB in virions. PLoS Pathog 2016; 12:e1005564 [View Article][PubMed]
     [Google Scholar]
  66. Bughio F, Umashankar M, Wilson J, Goodrum F. Human cytomegalovirus UL135 and UL136 genes are required for postentry tropism in endothelial cells. J Virol 2015; 89:6536–6550 [View Article][PubMed]
     [Google Scholar]
  67. Caló S, Cortese M, Ciferri C, Bruno L, Gerrein R et al. The human cytomegalovirus UL116 gene encodes an envelope glycoprotein forming a complex with gH independently from gL. J Virol 2016; 90:4926–4938 [View Article][PubMed]
     [Google Scholar]
  68. Luganini A, Cavaletto N, Raimondo S, Geuna S, Gribaudo G. Loss of the human cytomegalovirus US16 protein abrogates virus entry into endothelial and epithelial cells by reducing the virion content of the pentamer. J Virol 2017; 91:e00205-17 [View Article][PubMed]
     [Google Scholar]
  69. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350–1362 [View Article][PubMed]
     [Google Scholar]
  70. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370:1316–1326 [View Article][PubMed]
     [Google Scholar]
  71. Alford CA, Hayes K, Britt W. Primary cytomegalovirus infection in pregnancy: comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection. J Infect Dis 1988; 158:917–924 [View Article][PubMed]
     [Google Scholar]
  72. Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995; 171:1115–1121 [View Article][PubMed]
     [Google Scholar]
  73. Eggers M, Radsak K, Enders G, Reschke M. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol 2001; 63:135–142 [View Article][PubMed]
     [Google Scholar]
  74. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 2012; 32:1324–1331 [View Article][PubMed]
     [Google Scholar]
  75. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 2013; 8:e59863 [View Article][PubMed]
     [Google Scholar]
  76. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F et al. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011; 52:113–118 [View Article][PubMed]
     [Google Scholar]
  77. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 2008; 89:853–865 [View Article][PubMed]
     [Google Scholar]
  78. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 2012; 86:7444–7447 [View Article][PubMed]
     [Google Scholar]
  79. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci USA 2014; 111:17965–17970 [View Article][PubMed]
     [Google Scholar]
  80. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010; 84:1005–1013 [View Article][PubMed]
     [Google Scholar]
  81. Iwami S, Takeuchi JS, Nakaoka S, Mammano F, Clavel F et al. Cell-to-cell infection by HIV contributes over half of virus infection. eLife 2015; 4:e08150 [View Article][PubMed]
     [Google Scholar]
  82. Gerna G, Percivalle E, Perez L, Lanzavecchia A, Lilleri D. Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH/gL/pUL128L and trimer gH/gL/gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation. J Virol 2016; 90:6216–6223 [View Article][PubMed]
     [Google Scholar]
  83. Cui X, Adler SP, Schleiss MR, Arav-Boger R, Demmler Harrison GJ et al. Cytomegalovirus virions shed in urine have a reversible block to epithelial cell entry and are highly resistant to antibody neutralization. Clin Vaccine Immunol 2017; 24:e00024-17 [View Article][PubMed]
     [Google Scholar]
  84. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 2015; 163:988–998 [View Article][PubMed]
     [Google Scholar]
  85. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, Mcandrew E et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011; 366:8–19 [View Article][PubMed]
     [Google Scholar]
  86. Corrales-Aguilar E, Hoffmann K, Hengel H. CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol 2014; 36:627–640 [View Article][PubMed]
     [Google Scholar]
  87. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014; 6:228–238 [View Article][PubMed]
     [Google Scholar]
  88. Fu TM, An Z, Wang D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 2014; 32:2525–2533 [View Article][PubMed]
     [Google Scholar]
  89. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176–1178[PubMed]
     [Google Scholar]
  90. Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996; 70:2044–2048[PubMed]
     [Google Scholar]
  91. Adler SP, Manganello AM, Lee R, Mcvoy MA, Nixon DE et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimera vaccines in cytomegalovirus-seronegative men. J Infect Dis 2016; 214:1341–1348 [View Article][PubMed]
     [Google Scholar]
  92. Fu TM, Wang D, Freed DC, Tang A, Li F et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 2012; 30:7469–7474 [View Article][PubMed]
     [Google Scholar]
  93. Freed DC, Tang Q, Tang A, Li F, He X et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci USA 2013; 110:E4997E5005 [View Article][PubMed]
     [Google Scholar]
  94. Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW et al. Soluble human cytomegalovirus gH/gL/pUL128-131 pentameric complex, but not gH/gL, inhibits viral entry to epithelial cells and presents dominant native neutralizing epitopes. J Biol Chem 2015; 290:15985–15995 [View Article][PubMed]
     [Google Scholar]
  95. Ha S, Li F, Troutman MC, Freed DC, Tang A et al. Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH/gL/pUL128-131 pentameric complex. J Virol 2017; 91:e02033-1616 [View Article][PubMed]
     [Google Scholar]
  96. Wang D, Freed DC, He X, Li F, Tang A et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci Transl Med 2016; 8:362ra145 [View Article][PubMed]
     [Google Scholar]
  97. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E et al. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 2014; 10:e1004524 [View Article][PubMed]
     [Google Scholar]
  98. Bialas KM, Tanaka T, Tran D, Varner V, Cisneros de La Rosa E et al. Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. Proc Natl Acad Sci USA 2015; 112:13645–13650 [View Article][PubMed]
     [Google Scholar]
  99. Reap EA, Morris J, Dryga SA, Maughan M, Talarico T et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007; 25:7441–7449 [View Article][PubMed]
     [Google Scholar]
  100. Bernstein DI, Reap EA, Katen K, Watson A, Smith K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009; 28:484–493 [View Article][PubMed]
     [Google Scholar]
  101. Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013; 31:919–926 [View Article][PubMed]
     [Google Scholar]
  102. Wen Y, Monroe J, Linton C, Archer J, Beard CW et al. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 2014; 32:3796–3804 [View Article][PubMed]
     [Google Scholar]
  103. Cayatte C, Schneider-Ohrum K, Wang Z, Irrinki A, Nguyen N et al. Cytomegalovirus vaccine strain Towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol 2013; 87:11107–11120 [View Article][PubMed]
     [Google Scholar]
  104. Tomić A, Varanasi PR, Golemac M, Malić S, Riese P et al. Activation of innate and adaptive immunity by a recombinant human cytomegalovirus strain expressing an NKG2D ligand. PLoS Pathog 2016; 12:e1006015 [View Article][PubMed]
     [Google Scholar]
  105. Spaete RR, Saxena A, Scott PI, Song GJ, Probert WS et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 1990; 64:2922–2931[PubMed]
     [Google Scholar]
  106. Pass RF, Zhang C, Evans A, Simpson T, Andrews W et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191–1199 [View Article][PubMed]
     [Google Scholar]
  107. Griffiths PD, Stanton A, Mccarrell E, Smith C, Osman M et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377:1256–1263 [View Article][PubMed]
     [Google Scholar]
  108. Pötzsch S, Spindler N, Wiegers AK, Fisch T, Rücker P et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011; 7:e1002172 [View Article][PubMed]
     [Google Scholar]
  109. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005; 86:275–284 [View Article][PubMed]
     [Google Scholar]
  110. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T et al. Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol 2011; 85:5150–5158 [View Article][PubMed]
     [Google Scholar]
  111. Nogalski MT, Chan GC, Stevenson EV, Collins-Mcmillen DK, Yurochko AD. The HCMV gH/gL/UL128-131 complex triggers the specific cellular activation required for efficient viral internalization into target monocytes. PLoS Pathog 2013; 9:e1003463 [View Article][PubMed]
     [Google Scholar]
  112. Anderholm KM, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs 2016; 76:1625–1645 [View Article][PubMed]
     [Google Scholar]
  113. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D et al. Understanding and making use of human memory B cells. Immunol Rev 2006; 211:303–309 [View Article][PubMed]
     [Google Scholar]
  114. Ishida JH, Patel A, Mehta AK, Gatault P, Mcbride JM et al. Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of Cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob Agents Chemother 2017; 61:e0179416 [View Article][PubMed]
     [Google Scholar]
  115. Bia FJ, Griffith BP, Tarsio M, Hsiung GD. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis 1980; 142:732–738 [View Article][PubMed]
     [Google Scholar]
  116. Schleiss MR, Mcvoy MA. Guinea Pig Cytomegalovirus (GPCMV): A model for the study of the prevention and treatment of maternal-fetal transmission. Future Virol 2010; 5:207–212 [View Article][PubMed]
     [Google Scholar]
  117. Yamada S, Nozawa N, Katano H, Fukui Y, Tsuda M et al. Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 2009; 391:99–106 [View Article][PubMed]
     [Google Scholar]
  118. Auerbach M, Yan D, Fouts A, Xu M, Estevez A et al. Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread. Virology 2013; 441:75–84 [View Article][PubMed]
     [Google Scholar]
  119. Gnanandarajah JS, Gillis PA, Hernandez-Alvarado N, Higgins L, Markowski TW et al. Identification by mass spectrometry and immune response analysis of guinea pig cytomegalovirus (GPCMV) pentameric complex proteins GP129, 131 and 133. Viruses 2014; 6:727–751 [View Article][PubMed]
     [Google Scholar]
  120. Mcvoy MA, Wang JB, Dittmer DP, Bierle CJ, Swanson EC et al. Repair of a mutation disrupting the guinea pig cytomegalovirus pentameric complex acquired during fibroblast passage restores pathogenesis in immune-suppressed guinea pigs and in the context of congenital infection. J Virol 2016; 90:7715–7727 [View Article][PubMed]
     [Google Scholar]
  121. Auerbach MR, Yan D, Vij R, Hongo JA, Nakamura G et al. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog 2014; 10:e1004060 [View Article][PubMed]
     [Google Scholar]
  122. De Rijk E, Van Esch E. The macaque placenta-a mini-review. Toxicol Pathol 2008; 36:108S–118S [View Article]
     [Google Scholar]
  123. Costa-Garcia M, Vera A, Moraru M, Vilches C, López-Botet M et al. Antibody-mediated response of NKG2CbrightNK cells against human cytomegalovirus. J Immunol 2015; 194:2715–2724 [View Article][PubMed]
     [Google Scholar]
  124. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011; 108:14725–14732 [View Article][PubMed]
     [Google Scholar]
  125. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119:2665–2674 [View Article][PubMed]
     [Google Scholar]
  126. Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C et al. Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children. Eur J Immunol 2012; 42:3256–3266 [View Article][PubMed]
     [Google Scholar]
  127. Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C et al. Human cytomegalovirus-induced NKG2Chi CD57hi natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 2013; 87:7717–7725 [View Article][PubMed]
     [Google Scholar]
  128. Couzi L, Pitard V, Netzer S, Garrigue I, Lafon ME et al. Common features of γ/δ T cells and CD8+ α/ß T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis 2009; 200:1415–1424 [View Article][PubMed]
     [Google Scholar]
  129. Déchanet J, Merville P, Lim A, Retière C, Pitard V et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103:1437–1449 [View Article][PubMed]
     [Google Scholar]
  130. Lafarge X, Merville P, Cazin MC, Bergé F, Potaux L et al. Cytomegalovirus infection in transplant recipients resolves when circulating γδ T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 2001; 184:533–541 [View Article][PubMed]
     [Google Scholar]
  131. Fornara C, Lilleri D, Revello MG, Furione M, Zavattoni M et al. Kinetics of effector functions and phenotype of virus-specific and γδ T lymphocytes in primary human cytomegalovirus infection during pregnancy. J Clin Immunol 2011; 31:1054–1064 [View Article][PubMed]
     [Google Scholar]
  132. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M et al. Human cytomegalovirus elicits fetal γδ T cell responses in utero. J Exp Med 2010; 207:807–821 [View Article][PubMed]
     [Google Scholar]
  133. Pitard V, Roumanes D, Lafarge X, Couzi L, Garrigue I et al. Long-term expansion of effector memory Vδ2− γ/δ T cells is a specific blood signature of CMV infection. Blood 2008; 112:1317–1324 [View Article][PubMed]
     [Google Scholar]
  134. Halary F, Pitard V, Dlubek D, Krzysiek R, de La Salle H et al. Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201:1567–1578 [View Article][PubMed]
     [Google Scholar]
  135. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O et al. Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa). Blood 2012; 119:1418–1427 [View Article][PubMed]
     [Google Scholar]
  136. Lozza L, Lilleri D, Percivalle E, Fornara C, Comolli G et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005; 35:1795–1804 [View Article][PubMed]
     [Google Scholar]
  137. Fornara C, Furione M, Arossa A, Gerna G, Lilleri D. Comparative magnitude and kinetics of human cytomegalovirus-specific CD4+ and CD8+ T-cell responses in pregnant women with primary versus remote infection and in transmitting versus non-transmitting mothers: its utility for dating primary infection in pregnancy. J Med Virol 2016; 88:1238–1246 [View Article][PubMed]
     [Google Scholar]
  138. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med 2009; 206:1525–1534 [View Article][PubMed]
     [Google Scholar]
  139. Lilleri D, Gerna G. Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. Rev Med Virol 2017; 27:e1921 [View Article][PubMed]
     [Google Scholar]
  140. Gerna G, Lilleri D, Fornara C, Bruno F, Gabanti E et al. Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. J Gen Virol 2015; 96:360–369 [View Article][PubMed]
     [Google Scholar]
  141. Bruno F, Fornara C, Zelini P, Furione M, Carrara E et al. Follicular helper T-cells and virus-specific antibody response in primary and reactivated human cytomegalovirus infections of the immunocompetent and immunocompromised transplant patients. J Gen Virol 2016; 97:1928–1941 [View Article][PubMed]
     [Google Scholar]
  142. Leddon SA, Richards KA, Treanor JJ, Sant AJ. Abundance and specificity of influenza reactive circulating memory follicular helper and non-follicular helper CD4 T cells in healthy adults. Immunology 2015; 146:157–162 [View Article][PubMed]
     [Google Scholar]
  143. Schultz BT, Teigler JE, Pissani F, Oster AF, Kranias G et al. Circulating HIV-specific interleukin-21+CD4+ T cells represent peripheral Tfh cells with antigen-dependent helper functions. Immunity 2016; 44:167–178 [View Article][PubMed]
     [Google Scholar]
  144. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014; 41:529–542 [View Article][PubMed]
     [Google Scholar]
  145. Gabanti E, Bruno F, Lilleri D, Fornara C, Zelini P et al. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients. PLoS One 2014; 9:e106044 [View Article][PubMed]
     [Google Scholar]
  146. Gabanti E, Lilleri D, Ripamonti F, Bruno F, Zelini P et al. Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection. Biol Blood Marrow Transplant 2015; 21:2192–2202 [View Article][PubMed]
     [Google Scholar]
  147. Gerna G, Zavattoni M, Baldanti F, Furione M, Chezzi L et al. Circulating cytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. J Med Virol 1998; 55:64–74 [View Article][PubMed]
     [Google Scholar]
  148. Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol 2010; 20:136–155 [View Article][PubMed]
     [Google Scholar]
  149. Tong Y, Pang XL, Mabilangan C, Preiksaitis JK. Determination of the biological forms of human cytomegalovirus DNA in the plasma of solid-organ transplant recipients. J Infect Dis 2017; 215:1094–1101 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000882
Loading
The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development
J. Gen. Virol. 98, 2215 (2017); https://doi.org/10.1099/jgv.0.000882
/content/journal/jgv/10.1099/jgv.0.000882
/content/journal/jgv/10.1099/jgv.0.000882
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error